Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Genomics in drug discovery and development [[electronic resource] /] / Dimitri Semizarov, Eric Blomme
| Genomics in drug discovery and development [[electronic resource] /] / Dimitri Semizarov, Eric Blomme |
| Autore | Semizarov Dimitri |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2009 |
| Descrizione fisica | 1 online resource (496 p.) |
| Disciplina |
615
615.19 |
| Altri autori (Persone) | BlommeEric |
| Soggetto topico |
Pharmacogenomics
Drug development Genetic toxicology DNA microarrays |
| ISBN |
1-281-93869-6
9786611938697 0-470-40977-0 0-470-40976-2 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Genomics in Drug Discovery and Development; Contents; Preface; ACKNOWLEDGMENTS; 1. Introduction: Genomics and Personalized Medicine; 1.1. Fundamentals of Genomics; 1.2. The Concept of Personalized Medicine; 1.3. Genomics Technologies in Drug Discovery; 1.4. Scope of This Book; References; 2. Genomics Technologies as Tools in Drug Discovery; 2.1. Introduction to Genomics Technologies; 2.2. Gene Expression Microarrays: Technology; 2.2.1. Standard Microarray Protocol; 2.2.2. Monitoring the Quality of Input RNA for Microarray Experiments
2.2.3. Specialized Microarray Protocols for Archived and Small Samples2.2.4. Quality of Microarray Data and Technical Parameters of Microarrays; 2.2.5. Reproducibility of Expression Microarrays and Cross-Platform Comparisons; 2.2.6. Microarray Databases and Annotation of Microarray Data; 2.2.6.1. Target Identification; 2.2.6.2. Disease Classification; 2.2.6.3. Compound Assessment; 2.3. Gene Expression Microarrays: Data Analysis; 2.3.1. Identification of Significant Gene Expression Changes; 2.3.2. Sample Classification and Class Prediction with Expression Microarrays 2.3.3. Pathway Analysis with Gene Expression Microarrays2.3.4. Common Problems Affecting the Validity of Microarray Studies; 2.4. Comparative Genomic Hybridization: Technology; 2.5. Comparative Genomic Hybridization: Data Analysis; 2.6. Microarray-Based DNA Methylation Profiling; 2.7. Microarray-Based MicroRNA Profiling; 2.8. Technical Issues in Genomics Experiments and Regulatory Submissions of Microarray Data; 2.8.1. Study of a Drug's Mechanism of Action by Gene Expression Profiling; 2.8.2. Early Assessment of Drug Toxicity in Model Systems 2.8.3. Biomarker Identification in Discovery and Early Development2.8.4. Patient Stratification in Clinical Trials with Gene Expression Signatures; 2.8.5. Genotyping of Patients in Clinical Studies to Predict Drug Response; 2.9. Conclusion; References; 3. Genomic Biomarkers; 3.1. Introduction to Genomic Biomarkers; 3.2. DNA Biomarkers; 3.2.1. DNA Copy Number Alterations; 3.2.1.1. DNA Copy Number Alterations in Cancer; 3.2.1.2. DNA Copy Number Alterations in Other Diseases; 3.2.1.3. Identification of DNA Copy Number Biomarkers in Drug Discovery; 3.2.2. Mutations; 3.2.2.1. p53 Mutations 3.2.2.2. K-ras Mutations3.2.2.3. EGFR Mutations; 3.2.2.4. Bcr-abl and KIT Mutations; 3.2.3. Epigenetic Markers; 3.3. RNA Biomarkers; 3.3.1. Gene Expression Biomarkers Validated as Diagnostic Tests; 3.3.2. Other Examples of Gene Expression Biomarkers; 3.4. Clinical Validation of Genomic Biomarkers; References; 4. Fundamental Principles of Toxicogenomics; 4.1. Introduction; 4.2. Fundamentals of Toxicogenomics; 4.2.1. Principle of Toxicogenomics; 4.2.2. Technical Reproducibility; 4.2.3. Biological Reproducibility; 4.2.4. Species Extrapolation; 4.3. Analysis of Toxicogenomics Data 4.3.1. Compound-Induced Gene Expression Changes |
| Record Nr. | UNINA-9910144095703321 |
Semizarov Dimitri
|
||
| Hoboken, N.J., : Wiley, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Genomics in drug discovery and development [[electronic resource] /] / Dimitri Semizarov, Eric Blomme
| Genomics in drug discovery and development [[electronic resource] /] / Dimitri Semizarov, Eric Blomme |
| Autore | Semizarov Dimitri |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2009 |
| Descrizione fisica | 1 online resource (496 p.) |
| Disciplina |
615
615.19 |
| Altri autori (Persone) | BlommeEric |
| Soggetto topico |
Pharmacogenomics
Drug development Genetic toxicology DNA microarrays |
| ISBN |
1-281-93869-6
9786611938697 0-470-40977-0 0-470-40976-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Genomics in Drug Discovery and Development; Contents; Preface; ACKNOWLEDGMENTS; 1. Introduction: Genomics and Personalized Medicine; 1.1. Fundamentals of Genomics; 1.2. The Concept of Personalized Medicine; 1.3. Genomics Technologies in Drug Discovery; 1.4. Scope of This Book; References; 2. Genomics Technologies as Tools in Drug Discovery; 2.1. Introduction to Genomics Technologies; 2.2. Gene Expression Microarrays: Technology; 2.2.1. Standard Microarray Protocol; 2.2.2. Monitoring the Quality of Input RNA for Microarray Experiments
2.2.3. Specialized Microarray Protocols for Archived and Small Samples2.2.4. Quality of Microarray Data and Technical Parameters of Microarrays; 2.2.5. Reproducibility of Expression Microarrays and Cross-Platform Comparisons; 2.2.6. Microarray Databases and Annotation of Microarray Data; 2.2.6.1. Target Identification; 2.2.6.2. Disease Classification; 2.2.6.3. Compound Assessment; 2.3. Gene Expression Microarrays: Data Analysis; 2.3.1. Identification of Significant Gene Expression Changes; 2.3.2. Sample Classification and Class Prediction with Expression Microarrays 2.3.3. Pathway Analysis with Gene Expression Microarrays2.3.4. Common Problems Affecting the Validity of Microarray Studies; 2.4. Comparative Genomic Hybridization: Technology; 2.5. Comparative Genomic Hybridization: Data Analysis; 2.6. Microarray-Based DNA Methylation Profiling; 2.7. Microarray-Based MicroRNA Profiling; 2.8. Technical Issues in Genomics Experiments and Regulatory Submissions of Microarray Data; 2.8.1. Study of a Drug's Mechanism of Action by Gene Expression Profiling; 2.8.2. Early Assessment of Drug Toxicity in Model Systems 2.8.3. Biomarker Identification in Discovery and Early Development2.8.4. Patient Stratification in Clinical Trials with Gene Expression Signatures; 2.8.5. Genotyping of Patients in Clinical Studies to Predict Drug Response; 2.9. Conclusion; References; 3. Genomic Biomarkers; 3.1. Introduction to Genomic Biomarkers; 3.2. DNA Biomarkers; 3.2.1. DNA Copy Number Alterations; 3.2.1.1. DNA Copy Number Alterations in Cancer; 3.2.1.2. DNA Copy Number Alterations in Other Diseases; 3.2.1.3. Identification of DNA Copy Number Biomarkers in Drug Discovery; 3.2.2. Mutations; 3.2.2.1. p53 Mutations 3.2.2.2. K-ras Mutations3.2.2.3. EGFR Mutations; 3.2.2.4. Bcr-abl and KIT Mutations; 3.2.3. Epigenetic Markers; 3.3. RNA Biomarkers; 3.3.1. Gene Expression Biomarkers Validated as Diagnostic Tests; 3.3.2. Other Examples of Gene Expression Biomarkers; 3.4. Clinical Validation of Genomic Biomarkers; References; 4. Fundamental Principles of Toxicogenomics; 4.1. Introduction; 4.2. Fundamentals of Toxicogenomics; 4.2.1. Principle of Toxicogenomics; 4.2.2. Technical Reproducibility; 4.2.3. Biological Reproducibility; 4.2.4. Species Extrapolation; 4.3. Analysis of Toxicogenomics Data 4.3.1. Compound-Induced Gene Expression Changes |
| Record Nr. | UNINA-9910831197303321 |
|
Semizarov Dimitri
|
||
| Hoboken, N.J., : Wiley, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Genomics in drug discovery and development / / Dimitri Semizarov, Eric Blomme
| Genomics in drug discovery and development / / Dimitri Semizarov, Eric Blomme |
| Autore | Semizarov Dimitri |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2009 |
| Descrizione fisica | 1 online resource (496 p.) |
| Disciplina | 615/.19 |
| Altri autori (Persone) | BlommeEric |
| Soggetto topico |
Pharmacogenomics
Drug development Genetic toxicology DNA microarrays |
| ISBN |
1-281-93869-6
9786611938697 0-470-40977-0 0-470-40976-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Genomics in Drug Discovery and Development; Contents; Preface; ACKNOWLEDGMENTS; 1. Introduction: Genomics and Personalized Medicine; 1.1. Fundamentals of Genomics; 1.2. The Concept of Personalized Medicine; 1.3. Genomics Technologies in Drug Discovery; 1.4. Scope of This Book; References; 2. Genomics Technologies as Tools in Drug Discovery; 2.1. Introduction to Genomics Technologies; 2.2. Gene Expression Microarrays: Technology; 2.2.1. Standard Microarray Protocol; 2.2.2. Monitoring the Quality of Input RNA for Microarray Experiments
2.2.3. Specialized Microarray Protocols for Archived and Small Samples2.2.4. Quality of Microarray Data and Technical Parameters of Microarrays; 2.2.5. Reproducibility of Expression Microarrays and Cross-Platform Comparisons; 2.2.6. Microarray Databases and Annotation of Microarray Data; 2.2.6.1. Target Identification; 2.2.6.2. Disease Classification; 2.2.6.3. Compound Assessment; 2.3. Gene Expression Microarrays: Data Analysis; 2.3.1. Identification of Significant Gene Expression Changes; 2.3.2. Sample Classification and Class Prediction with Expression Microarrays 2.3.3. Pathway Analysis with Gene Expression Microarrays2.3.4. Common Problems Affecting the Validity of Microarray Studies; 2.4. Comparative Genomic Hybridization: Technology; 2.5. Comparative Genomic Hybridization: Data Analysis; 2.6. Microarray-Based DNA Methylation Profiling; 2.7. Microarray-Based MicroRNA Profiling; 2.8. Technical Issues in Genomics Experiments and Regulatory Submissions of Microarray Data; 2.8.1. Study of a Drug's Mechanism of Action by Gene Expression Profiling; 2.8.2. Early Assessment of Drug Toxicity in Model Systems 2.8.3. Biomarker Identification in Discovery and Early Development2.8.4. Patient Stratification in Clinical Trials with Gene Expression Signatures; 2.8.5. Genotyping of Patients in Clinical Studies to Predict Drug Response; 2.9. Conclusion; References; 3. Genomic Biomarkers; 3.1. Introduction to Genomic Biomarkers; 3.2. DNA Biomarkers; 3.2.1. DNA Copy Number Alterations; 3.2.1.1. DNA Copy Number Alterations in Cancer; 3.2.1.2. DNA Copy Number Alterations in Other Diseases; 3.2.1.3. Identification of DNA Copy Number Biomarkers in Drug Discovery; 3.2.2. Mutations; 3.2.2.1. p53 Mutations 3.2.2.2. K-ras Mutations3.2.2.3. EGFR Mutations; 3.2.2.4. Bcr-abl and KIT Mutations; 3.2.3. Epigenetic Markers; 3.3. RNA Biomarkers; 3.3.1. Gene Expression Biomarkers Validated as Diagnostic Tests; 3.3.2. Other Examples of Gene Expression Biomarkers; 3.4. Clinical Validation of Genomic Biomarkers; References; 4. Fundamental Principles of Toxicogenomics; 4.1. Introduction; 4.2. Fundamentals of Toxicogenomics; 4.2.1. Principle of Toxicogenomics; 4.2.2. Technical Reproducibility; 4.2.3. Biological Reproducibility; 4.2.4. Species Extrapolation; 4.3. Analysis of Toxicogenomics Data 4.3.1. Compound-Induced Gene Expression Changes |
| Record Nr. | UNINA-9910877991603321 |
|
Semizarov Dimitri
|
||
| Hoboken, N.J., : Wiley, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||